Multicenter prospective randomized, double-blind comparative study between lanthanum carbonate and calcium carbonate as phosphate binders in Japanese hemodialysis patients with hyperphosphatemia

2008 ◽  
Vol 70 (11) ◽  
pp. 404-410 ◽  
Author(s):  
T. Shigematsu ◽  
the Lanthanum Carbonate Group
Keyword(s):  
Calcium Carbonate ◽  
Comparative Study ◽  
Hemodialysis Patients ◽  
Lanthanum Carbonate ◽  
Phosphate Binders ◽  
Double Blind

scholarly journals A comparison between the combined effect of calcium carbonate with sucroferric oxyhydroxide and other phosphate binders: an in vitro and in vivo experimental study

2019 ◽  
Vol 20 (1) ◽  
Author(s):  
Atsushi Yaguchi ◽  
Kenji Akahane ◽  
Kumi Tsuchioka ◽  
Saori Yonekubo ◽  
Shota Yamamoto ◽  
...  
Keyword(s):  
Calcium Carbonate ◽  
Lanthanum Carbonate ◽  
Combined Effect ◽  
Ferric Citrate ◽  
Phosphate Binders ◽  
Phosphate Solution ◽  
Phosphate Binding ◽  
Sevelamer Hydrochloride

Abstract Background Approximately 30% of patients on dialysis received combination therapy for their phosphate binder prescription; however, few studies for combined effects of phosphate binders are reported. For the purpose of evaluating the efficacy of combination therapy, we compared the efficacy of sucroferric oxyhydroxide (PA21) combined with calcium carbonate with that of lanthanum carbonate hydrate, sevelamer hydrochloride, and ferric citrate hydrate combined with calcium carbonate. Methods For in vitro studies, calcium carbonate and the other phosphate binders alone or in combination were stirred in phosphate solution at pH 2–8 for 2 h. After centrifuging the suspension, the phosphorus level in the supernatant was determined. For in vivo studies, rats were orally administered calcium carbonate and the other phosphate binders (except for sevelamer hydrochloride) alone or in combination, followed by oral administration of phosphate solution adjusted to pH 2 or 7. Serum samples were collected from the rats at predetermined timepoints and the serum phosphorus levels were determined and analyzed using a two-way analysis of variance. Results In the in vitro study, the measured phosphate-binding capacity of combining sevelamer hydrochloride, PA21, and lanthanum carbonate hydrate with calcium carbonate was approximately equal to or greater than the theoretical values under most conditions. Furthermore, these combined effects were insensitive to pH in that order. The measured phosphate-binding capacity of ferric citrate hydrate combined with calcium carbonate was smaller than the theoretical values, and the combination did not exhibit efficacy under any of the tested conditions. In the in vivo study, the combined effect of PA21 and calcium carbonate at both pH values and that of lanthanum carbonate hydrate and calcium carbonate at pH 2 were additive. In contrast, the combined effect of lanthanum carbonate hydrate and calcium carbonate at pH 7 and that of ferric citrate hydrate and calcium carbonate at pH 2 were antagonistic. Conclusions These results suggest that coadministration of PA21 and calcium carbonate showed good and relatively stable efficacy throughout the range of the gastrointestinal pH and that combining lanthanum carbonate hydrate and ferric citrate hydrate with calcium carbonate may not produce the expected efficacy under certain conditions.

Differences in gastrointestinal calcium absorption after the ingestion of calcium-free phosphate binders

2014 ◽  
Vol 306 (1) ◽  
pp. F61-F67 ◽  
Author(s):  
Geert J. Behets ◽  
Geert Dams ◽  
Stephen J. Damment ◽  
Patrick Martin ◽  
Marc E. De Broe ◽  
...  
Keyword(s):  
Renal Failure ◽  
Renal Function ◽  
Calcium Carbonate ◽  
Normal Renal Function ◽  
Calcium Absorption ◽  
Lanthanum Carbonate ◽  
Ionized Calcium ◽  
Phosphate Binders ◽  
Calcium Balance ◽  
Sevelamer Carbonate

Both calcium-containing and noncalcium-containing phosphate binders can increase gastrointestinal calcium absorption. Previously, we observed that lanthanum carbonate administration to rats with renal failure is not associated with increased calciuria. Additionally, lanthanum carbonate treatment in dialysis patients has been associated with a less pronounced initial decrease in serum parathyroid hormone compared with other phosphate binders. For 8 days, male Wistar rats received a diet supplemented with 2% lanthanum carbonate, 2% sevelamer, 2% calcium carbonate, or 2% cellulose. Calciuria was found to be increased in animals with normal renal function treated with sevelamer or calcium carbonate but not with lanthanum carbonate. In animals with renal failure, cumulative calcium excretion showed similar results. In rats with normal renal function, serum ionized calcium levels were increased after 2 days of treatment with sevelamer, while calcium carbonate showed a smaller increase. Lanthanum carbonate did not induce differences. In animals with renal failure, no differences were found between sevelamer-treated, calcium carbonate-treated, and control groups. Lanthanum carbonate, however, induced lower ionized calcium levels within 2 days of treatment. These results were confirmed in normal human volunteers, who showed lower net calcium absorption after a single dose of lanthanum carbonate compared with sevelamer carbonate. In conclusion, these two noncalcium-containing phosphate-binding agents showed a differential effect on gastrointestinal calcium absorption. These findings may help to improve the management of calcium balance in patients with renal failure, including concomitant use of vitamin D.

scholarly journals Calcium acetate versus calcium carbonate in the control of hyperphosphatemia in hemodialysis patients

2000 ◽  
Vol 118 (6) ◽  
pp. 179-184 ◽  
Author(s):  
Eufrônio José d'Almeida Filho ◽  
Elisa de Albuquerque Sampaio da Cruz ◽  
Marcos Hoette ◽  
Frederico Ruzany ◽  
Luana Neves Lopes Keen ◽  
...  
Keyword(s):  
Calcium Carbonate ◽  
Statistical Significance ◽  
Blood Gas Analysis ◽  
Good Alternative ◽  
Hemodialysis Patients ◽  
Gas Analysis ◽  
Calcium Acetate ◽  
Double Blind Study ◽  
Double Blind ◽  
Stage Renal Disease

CONTEXT: Hyperphosphatemia has an important role in the development of bone and mineral abnormalities in end-stage renal disease (ESRD). OBJECTIVE: To compare the phosphorus binding power and the hypercalcemic effect of calcium acetate and calcium carbonate in hemodialysis patients. TYPE OF STUDY: Crossover, randomized, double-blind study. PLACE: A private hospital dialysis center. PARTICIPANTS: Fifty-two patients who were undergoing regular hemodialysis three times a week ([Ca++] dialysate = 3.5 mEq/L). PROCEDURES: Half of the patients were started on 5.6 g/day of calcium acetate and, after a 2 week washout period, received 6.2 g/day of calcium carbonate. The other half followed an inverse protocol. MAIN MEASUREMENTS: Clinical interviews were conducted 3 times a week to monitor for side effects. Determinations of serum urea, calcium, phosphorus, hematocrit, Kt/V and blood gas analysis were obtained before and after each treatment. RESULTS: Twenty-three patients completed the study. A significant increase in calcium plasma levels was only observed after treatment with calcium carbonate [9.34 mg/dl (SD 0.91) vs. 9.91 mg/dl (SD 0.79), P < 0.01]. The drop in phosphorus levels was substantial and significant for both salts [5.64 mg/dl (SD 1.54) vs. 4.60 mg/dl (SD 1.32), P < 0.01 and 5.89 mg/dl (SD 1.71) vs. 4.56 mg/dl (SD 1.57), P < 0.01, for calcium acetate and calcium carbonate respectively]. The percentage reduction in serum phosphorus (at the end of the study) per milliequivalent of salt administered per day tended to be higher with calcium acetate but statistical significance was not found. CONCLUSION: Calcium acetate can be a good alternative to calcium carbonate in the handling of hyperphosphatemia in ESRD patients. When calcium acetate is used, control of hyperphosphatemia can be achieved with a lower administration of calcium, perhaps with a lower risk of hypercalcemia.

Lanthanum Carbonate Is an Effective Hypophosphatemic Agent for Hemodialysis Patients Intolerant of Other Phosphate Binders

2010 ◽  
Vol 20 (4) ◽  
pp. 270-277 ◽  
Author(s):  
Wing Lam Winnie Chan ◽  
Karen Rounsley ◽  
Emma Chapman ◽  
Katherine Collings ◽  
Clare Dale ◽  
...  
Keyword(s):  
Hemodialysis Patients ◽  
Lanthanum Carbonate ◽  
Phosphate Binders

Effect of lanthanum carbonate vs. calcium carbonate on serum calcium in hemodialysis patients: a crossover study

2012 ◽  
Vol 78 (09) ◽  
pp. 216-223 ◽  
Author(s):  
Tatsunori Toida ◽  
Keiichi Fukudome ◽  
Shouichi Fujimoto ◽  
Kazuhiro Yamada ◽  
Yuji Sato ◽  
...  
Keyword(s):  
Calcium Carbonate ◽  
Crossover Study ◽  
Serum Calcium ◽  
Hemodialysis Patients ◽  
Lanthanum Carbonate

Calcium Acetate versus Calcium Carbonate as Phosphate Binders in Hemodialysis Patients

Nephron ◽  
1992 ◽  
Vol 60 (4) ◽  
pp. 423-427 ◽  
Author(s):  
F. Caravaca ◽  
I. Santos ◽  
J.J. Cubero ◽  
J.F. Esparrago ◽  
M. Arrobas ◽  
...  
Keyword(s):  
Calcium Carbonate ◽  
Hemodialysis Patients ◽  
Calcium Acetate ◽  
Phosphate Binders
Sign in / Sign up

Export Citation Format

Share Document